Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

BACKGROUND: Oncolytic viruses (OVs) are capable to inflame the tumor microenvironment (TME) and elicit infiltrating tumor-specific T cell responses. However, OV treatment negatively alters the cancer-immune set point in tumors to attenuate the antitumor immune response, which suggests the necessity...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Fei, Luo, Yong, Lin, Chaolong, Jia, Xian, Xu, Zilong, Tian, Rui, Lin, Yanhua, Zhao, Min, Chang, Yating, Huang, Xiaoxuan, Li, Shaopeng, Ren, Wenfeng, Qin, Yaning, Yu, Mengqin, Jia, Jizong, Han, Jinle, Luo, Wenxin, Zhang, Jun, Fu, Guo, Ye, Xiangzhong, Huang, Chenghao, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189843/
https://www.ncbi.nlm.nih.gov/pubmed/35688558
http://dx.doi.org/10.1136/jitc-2022-004762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189843/
https://www.ncbi.nlm.nih.gov/pubmed/35688558
http://dx.doi.org/10.1136/jitc-2022-004762

Ejemplares similares